CN113647902A - Method for in vivo noninvasive detection of mild cognitive dysfunction of human - Google Patents
Method for in vivo noninvasive detection of mild cognitive dysfunction of human Download PDFInfo
- Publication number
- CN113647902A CN113647902A CN202010399342.0A CN202010399342A CN113647902A CN 113647902 A CN113647902 A CN 113647902A CN 202010399342 A CN202010399342 A CN 202010399342A CN 113647902 A CN113647902 A CN 113647902A
- Authority
- CN
- China
- Prior art keywords
- scan
- mild cognitive
- human
- reho
- alff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000001727 in vivo Methods 0.000 title claims abstract description 12
- 238000001514 detection method Methods 0.000 title claims abstract description 7
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims abstract description 6
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000007781 pre-processing Methods 0.000 claims description 9
- 238000012937 correction Methods 0.000 claims description 4
- 230000004886 head movement Effects 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000010832 independent-sample T-test Methods 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims 3
- 230000005284 excitation Effects 0.000 claims 3
- 238000007405 data analysis Methods 0.000 claims 1
- 238000002592 echocardiography Methods 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 14
- 230000003557 neuropsychological effect Effects 0.000 abstract description 4
- 230000003920 cognitive function Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000000284 resting effect Effects 0.000 abstract description 3
- 230000008925 spontaneous activity Effects 0.000 abstract description 3
- 230000005856 abnormality Effects 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 16
- 239000011229 interlayer Substances 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000002360 prefrontal effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2576/00—Medical imaging apparatus involving image processing or analysis
- A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
- A61B2576/026—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- High Energy & Nuclear Physics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
The invention belongs to the technical field of biomedical engineering, and particularly relates to a method for detecting mild cognitive dysfunction in human in vivo in a non-invasive manner, which comprises the following steps: the testee is taken into a magnetic resonance examination room, firstly, a transverse section T2WI and T2_ FLAIR and a sagittal plane 3DT1WI sequence are adopted for scanning, then rs-fMRI sequence scanning is carried out, and finally, the obtained scanning data is preprocessed and analyzed to obtain an ALFF value and a ReHo value. The method utilizes the low-frequency Amplitude (ALFF) and the local consistency (ReHo) of the resting state functional magnetic resonance imaging and different measurement indexes to find the abnormality of the brain spontaneous activity of the MCI patient from different angles, achieves the purposes of noninvasive detection of the cognitive function of the human body, has objective results compared with the method of a neuropsychological scale used in the prior art, and can realize the rechecking in a short period, the tracking of the clinical treatment effect and the prognosis condition of the patient.
Description
Technical Field
The invention belongs to the technical field of biomedical engineering, and particularly relates to a method for detecting mild cognitive dysfunction in a human body in a non-invasive manner in vivo.
Background
Mild Cognitive Impairment (MCI) is a prodromal phase of alzheimer's disease, the population has normal daily living abilities, but has a condition of memory or cognitive impairment, alzheimer's disease will develop without intervention, MCI can also recover to a normal cognitive state after appropriate intervention measures are taken, and currently, MCI is detected mainly by neuropsychological scales, PET and brain histopathological examination, the scales comprise a simple intelligent mental state examination table (MMSE), a montreal cognitive assessment table (MoCA-B) and the like.
Subjective factors exist in the neuropsychological scale inspection, the inspection result is related to various factors such as the education degree, the mental state, the psychological state, the inspection environment and the like of a testee, the specificity is poor, and certain missed diagnosis and misdiagnosis exist; at present, most scales are China normals directly introduced abroad without scales, and are not necessarily suitable for China; in addition, the neuropsychological scale is not suitable for short-term follow-up and reexamination due to the learning effect, and cannot be applied to clinical treatment effect evaluation. PET examinations are difficult to popularize because of unavoidable ionizing radiation and high examination costs. The brain histopathological examination can only be performed after death of the human body and can not find early lesions, which is not really helpful for clinical diagnosis and treatment, improvement of life of patients and even burden of the whole society.
Disclosure of Invention
In order to overcome the problems of the prior art, the invention aims to provide a method for detecting mild cognitive dysfunction in a human in a non-invasive manner in vivo,
the technical content of the invention is as follows:
the invention provides a method for detecting mild cognitive dysfunction in a human body in a non-invasive manner, which comprises the following steps:
carrying the testee into a magnetic resonance examination room, firstly scanning sequences of T2WI and T2_ FLAIR and a sagittal plane 3DT1WI in a cross section, then scanning an rs-fMRI sequence, and finally preprocessing and analyzing the obtained scanning data to obtain an ALFF value and a ReHo value, wherein the ALFF is the height of the amplitude level of the spontaneous activity of the brain, and the higher the ALFF value is, the higher the efficiency of signal transmission and processing is; the increase and decrease of the ReHo value prompt the synchronous increase and decrease of the spontaneous brain activities of local neurons, and the abnormal increase or decrease of the ReHo reflects the local damage of the spontaneous nerve activity synchronism of the corresponding brain area and prompts functional defects.
The T2WI scan includes using a fast spin echo scan (TSE), the scan parameters including: TR 6000.0ms, TE 125.0ms, number of layers 24, layer thickness 5mm, inter-layer distance 1mm, matrix 384 × 384, FOV 240 × 240mm, voxel size 0.6 × 0.6 × 5.0mm3Excitation times are 1, the turning angle is 90 degrees, and the duration time is 1 min;
the T2_ FLAIR scan includes using fast spin echo (TIR) with inversion pulses, the scan parameters include TR 8500.0ms, TE 81.0ms, number of layers 24, layer thickness 5mm, layer spacing 1mm, matrix 224 × 320, FOV 240 × 240mm, voxel size 0.7 × 0.8 × 5.0mm3Excitation frequency is 1, the turning angle is 150 degrees, and the duration time is 1min 59 s;
the scanning parameters of the high-resolution structure image of the sagittal 3DT1WI include TR 2530.0ms, TE 2.96ms, layer thickness 1.00mm, interlayer spacing 0.5mm, matrix 256 × 256, FOV 256 × 256mm, and voxel size 1 × 1 × 1mm3Excitation times are 1, a turning angle is 9 degrees, and the duration is 4min and 30 s;
the functional image EPI _ BOLD scanning parameters comprise TR 2000ms, TE 30.0ms, layer thickness 3.5mm, layer spacing 0.91mm, matrix 64 × 64, FOV 224 × 224mm, and voxel size 3.5 × 3.5 × 3.5mm3The turning angle is 90 degrees, the collection times are 240, and the duration is 8min and 06 s;
the preprocessing and analysis of the scanning data comprises preprocessing all magnetic resonance scanning imaging data by using a Statistical parameter map 12 (SPM 12) software package to obtain ALFF (effective magnetic resonance imaging) and ReHo (ReHo) parameters of each testee;
and then, performing two independent sample t tests on ALFF values and ReHo values between two groups of testees by adopting a statistical tool in a DPABI14.0 software package, correcting by taking the parameters of head movement, age, education degree and gender as covariates, and performing Alphasim multiple comparison correction on the result.
Compared with the prior art, the invention has the following beneficial effects:
the invention relates to a method for detecting mild cognitive dysfunction of a human body in a non-invasive manner, which discovers the abnormality of the spontaneous activity of the brain of a MCI patient from different angles by using low-frequency Amplitude (ALFF) and local consistency (ReHo) of resting state functional magnetic resonance imaging and different measurement indexes, and achieves the purposes of detecting the cognitive function of the human body in a non-invasive manner and on the physical examination.
Drawings
FIG. 1 MRI tomographs of different brain regions between the MCI and NC groups;
FIG. 2 MRI tomographs of brain regions with MCI set ReHo values higher than NC set.
Detailed Description
The present invention is described in further detail in the following description of specific embodiments and the accompanying drawings, it is to be understood that these embodiments are merely illustrative of the present invention and are not intended to limit the scope of the invention, which is defined by the appended claims, and modifications thereof by those skilled in the art after reading this disclosure that are equivalent to the above described embodiments.
All the raw materials and reagents of the invention are conventional market raw materials and reagents unless otherwise specified.
Example 1
A method for in vivo non-invasive detection of mild cognitive impairment in a human, comprising the steps of:
1) recruiting volunteers, including according to the group entry standard and the exclusion standard, and dividing the test results into MCI groups and healthy control (NC) groups (30 cases each, 60 cases in total) according to the MOCA-B scale test results of the testees;
taking a subject into a magnetic resonance examination room, firstly scanning sequences of a cross section T2WI, a cross section T2_ FLAIR and a sagittal plane 3DT1WI, then scanning rs-fMRI sequences, and finally preprocessing and analyzing obtained scanning data to obtain an ALFF value and a ReHo value;
the T2WI scan includes using a fast spin echo scan (TSE), the scan parameters including: TR 6000.0ms, TE 125.0ms, number of layers 24, layer thickness 5mm, inter-layer distance 1mm, matrix 384 × 384, FOV 240 × 240mm, voxel size 0.6 × 0.6 × 5.0mm3Excitation times are 1, the turning angle is 90 degrees, and the duration time is 1 min;
the T2_ FLAIR scan includes using fast spin echo (TIR) with inversion pulses, the scan parameters include TR 8500.0ms, TE 81.0ms, number of layers 24, layer thickness 5mm, layer spacing 1mm, matrix 224 × 320, FOV 240 × 240mm, voxel size 0.7 × 0.8 × 5.0mm3Excitation frequency is 1, the turning angle is 150 degrees, and the duration time is 1min 59 s;
the scanning parameters of the high-resolution structure image of the sagittal 3DT1WI include TR 2530.0ms, TE 2.96ms, layer thickness 1.00mm, interlayer spacing 0.5mm, matrix 256 × 256, FOV 256 × 256mm, and voxel size 1 × 1 × 1mm3Excitation times are 1, a turning angle is 9 degrees, and the duration is 4min and 30 s;
the functional image EPI _ BOLD scanning parameters comprise TR 2000ms, TE 30.0ms, layer thickness 3.5mm, layer spacing 0.91mm, matrix 64 × 64, FOV 224 × 224mm, and voxel size 3.5 × 3.5 × 3.5mm3The flip angle is 90 degrees, the collection times are 240, and the duration is 8min06 s;
2) the preprocessing and analysis of the scan data comprise preprocessing all magnetic resonance scan imaging data by using a Statistical parameter map 12 (SPM 12) based software package to obtain ALFF and ReHo parameters of each subject, wherein the obtained data are shown in table 1 and table 2;
TABLE 1 ALFF values between MCI and NC groups
Note: BA: a Brodmann partition; MNI: montreal neurological institute; k1 and K2 represent cluster 1 and cluster 2 respectively; the Peak point refers to the point with the maximum t value, namely the strongest active point.
TABLE 2 Difference brain regions between ReHo values in NC and MCI groups
Note: BA: a Brodmann partition; MNI: montreal neurological institute; k1 and K2 represent cluster 1 and cluster 2 respectively; the Peak point refers to the point with the maximum t value, namely the strongest active point.
3) And then, performing two independent sample t tests on ALFF values and ReHo values between two groups of testees by adopting a statistical tool in a DPABI14.0 software package, correcting by taking the parameters of head movement, age, education degree and gender as covariates, and performing Alphasim multiple comparison correction on the result.
The results show that compared with the NC group, the brain regions with increased ALFF values of the MCI group are mainly located in the left lenticular nucleus, thalamus and extend partially to the left inner capsule hind limb, the BA compartment is mainly located at BA48 and partially located at BA 37; the brain with reduced ALFF value is mainly located in the left dorsolateral superior gyrus, and partially extends to the midrib gyrus, the BA division is mainly located in BA10, and the BA 46 and BA 9 are partially located;
in summary, ALFF changes in MCI patients are mainly manifested in The cognitive function loop formed by The dorsolateral prefrontal cortex (DLPFC) and cortex-striatum-thalamus-cortex (CSTC) loops;
as shown in fig. 2, the ReHo values in the MCI group were elevated by two clusters (cluster, K) compared to the NC group, with the 1 st K brain region located predominantly in the left roland dick cap (Rolandic Operculum), the left inferior frontal island cap and extending partially to the left central anterior, BA partition predominantly in BA48 and partially in BA 44; the 2 nd cerebral area is mainly located in the left precordial and frontal gyrus, and the BA partition is BA 6; the differences are statistically significant (P < 0.05, Alphasim correction);
in summary, in the resting state, compared to the NC group, the subject MCI showed an increase in ReHo values in the language-dependent brain region including the forehead network, such as the left rowland dick island canopy, the left prefrontal island canopy, the left precordial gyrus, and the left prefrontal gyrus, and the working memory brain region, indicating an increase in the synchronization of the local neuronal spontaneous brain activity.
Claims (7)
1. A method for detecting mild cognitive dysfunction in a human in vivo in a non-invasive manner, comprising the steps of: the testee is taken into a magnetic resonance examination room, firstly, a transverse section T2WI and T2_ FLAIR and a sagittal plane 3DT1WI sequence are adopted for scanning, then rs-fMRI sequence scanning is carried out, and finally, the obtained scanning data is preprocessed and analyzed to obtain an ALFF value and a ReHo value.
2. The method for non-invasively detecting mild cognitive impairment in a human in vivo as set forth in claim 1, wherein the T2WI scan comprises a fast spin echo scan, and the scan parameters comprise: TR 6000.0ms, TE 125.0ms, layer number 24, layer thickness 5mm, layer spacing 1mm, matrix 384 × 384, FOV 240 × 240mm, voxel size 0.6 × 0.6 × 5.0mm, and an excitation number 1, flip angle 90 °, duration 1 min.
3. The method for non-invasive in vivo detection of mild cognitive impairment in a human according to claim 1, wherein the T2_ FLAIR scan comprises the use of fast spin echoes with inversion pulses and the scan parameters comprise TR 8500.0ms, TE 81.0ms, number of layers 24, layer thickness 5mm, layer spacing 1mm, matrix 224 x 320, FOV 240 x 240mm, voxel size 0.7 x 0.8 x 5.0mm, excitation number 1, flip angle 150 °, duration 1min 59 s.
4. The method for non-invasive in vivo detection of mild cognitive impairment in humans according to claim 1, wherein the scan parameters of the high resolution texture of the sagittal 3DT1WI include TR 2530.0ms, TE 2.96ms, layer thickness 1.00mm, layer spacing 0.5mm, matrix 256 x 256, FOV 256 x 256mm, voxel size 1 x 1mm, excitation number 1, flip angle 9 °, duration 4min 30 s.
5. The method for non-invasively detecting mild cognitive impairment in a human in vivo according to claim 1, wherein the functional image EPI-BOLD scan parameters comprise TR 2000ms, TE 30.0ms, layer thickness 3.5mm, layer spacing 0.91mm, matrix 64 x 64, FOV 224 x 224mm, voxel size 3.5 x 3.5mm for thin film scan, flip angle 90 °, acquisition times 240, duration 8min06 s.
6. The method for non-invasively detecting mild cognitive impairment in humans according to claim 1, wherein the pre-processing of the scan data comprises pre-processing all magnetic resonance scan imaging data using a statistical parameter-based map 12 software package to derive ALFF and ReHo parameters for each subject.
7. The method for non-invasive in vivo detection of mild cognitive impairment in humans according to claim 1, wherein the pre-processing of the data analysis comprises performing a two-independent sample t-test on the ALFF value and ReHo value of the subject using statistical tools in the DPABI14.0 software package, with correction using head movement parameters, age, education level and gender as covariates, and the results are corrected using Alphasim multiple comparisons.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010399342.0A CN113647902A (en) | 2020-05-12 | 2020-05-12 | Method for in vivo noninvasive detection of mild cognitive dysfunction of human |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010399342.0A CN113647902A (en) | 2020-05-12 | 2020-05-12 | Method for in vivo noninvasive detection of mild cognitive dysfunction of human |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113647902A true CN113647902A (en) | 2021-11-16 |
Family
ID=78488801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010399342.0A Pending CN113647902A (en) | 2020-05-12 | 2020-05-12 | Method for in vivo noninvasive detection of mild cognitive dysfunction of human |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113647902A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376549A (en) * | 2022-01-10 | 2022-04-22 | 杭州师范大学 | Cognitive function assessment and prediction system for cerebral hemorrhage minimally invasive surgery |
-
2020
- 2020-05-12 CN CN202010399342.0A patent/CN113647902A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376549A (en) * | 2022-01-10 | 2022-04-22 | 杭州师范大学 | Cognitive function assessment and prediction system for cerebral hemorrhage minimally invasive surgery |
| CN114376549B (en) * | 2022-01-10 | 2024-03-22 | 杭州师范大学 | Cognitive function evaluation and prediction system for cerebral hemorrhage minimally invasive surgery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hinkley et al. | Clinical symptoms and alpha band resting-state functional connectivity imaging in patients with schizophrenia: implications for novel approaches to treatment | |
| Marques et al. | Cognitive decline in temporal lobe epilepsy due to unilateral hippocampal sclerosis | |
| Lindgren et al. | Thalamic metabolic rate predicts EEG alpha power in healthy control subjects but not in depressed patients | |
| Majos et al. | Cortical mapping by functional magnetic resonance imaging in patients with brain tumors | |
| Henry et al. | Clinical evaluation of interictal fluorine-18-fluorodeoxyglucose PET in partial epilepsy | |
| CN109276228B (en) | System and device for detecting brain function | |
| CN105708462A (en) | Data processing method based on rfMRI (resting-state functional magnetic resonance imaging) of idiopathic epilepsy | |
| US20210369147A1 (en) | Multimodal Neuroimaging-Based Diagnostic Systems and Methods for Detecting Tinnitus | |
| Rossini et al. | Analysis of interhemispheric asymmetries of somatosensory evoked magnetic fields to right and left median nerve stimulation | |
| CN110689536A (en) | Method and device for tracking grey matter and white matter of brain based on multi-modal magnetic resonance image | |
| CN110555844A (en) | application of functional magnetic resonance imaging (fMRI) technology in analysis of activity change of human brain region | |
| Di Paola et al. | The structure of the corpus callosum in obsessive compulsive disorder | |
| Griffith et al. | A controlled quantitative MRI volumetric investigation of hippocampal contributions to immediate and delayed memory performance | |
| Köhler et al. | Electrophysiological changes in late life depression and their relation to structural brain changes | |
| Wang et al. | Functional alterations in resting-state visual networks in high-tension glaucoma: an independent component analysis | |
| Murnane et al. | Development of an apparatus and methodology for conducting functional magnetic resonance imaging (fMRI) with pharmacological stimuli in conscious rhesus monkeys | |
| Huang et al. | Electrophysiological signatures of the resting-state fMRI global signal: a simultaneous EEG-fMRI study | |
| Griffith et al. | Memory relationships between MRI volumes and resting PET metabolism of medial temporal lobe structures | |
| Frøkjær et al. | Integrity of central nervous function in diabetes mellitus assessed by resting state EEG frequency analysis and source localization | |
| CN113647902A (en) | Method for in vivo noninvasive detection of mild cognitive dysfunction of human | |
| Wang et al. | White matter abnormalities in medication-naïve adult patients with major depressive disorder: Tract-based spatial statistical analysis | |
| Kuperman et al. | Neuroimaging in child and adolescent psychiatry | |
| Erickson et al. | Neural basis of the visual working memory deficit in schizophrenia: merging evidence from fMRI and EEG | |
| Milner et al. | Towards neural correlates of auditory stimulus processing: a simultaneous auditory evoked potentials and functional magnetic resonance study using an odd-ball paradigm | |
| Pinner et al. | Covariation between brain function (MEG) and structure (DTI) differentiates adolescents with fetal alcohol spectrum disorder from typically developing controls |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211116 |
|
| WD01 | Invention patent application deemed withdrawn after publication |